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Two trials have assessed the use of canakinumab and anakinra in patients with new-onset type 1 diabetes mellitus (T1DM). Although fairly safe, the drugs were not efficacious in terms of halting the decline in β-cell function. Is this the end of the line for targeting IL-1 in T1DM? A major focus of research in the past few years has been the development of immuno therapies for type 1 diabetes melli tus (T1DM), an autoimmune disease that can manifest as early as 6 months of age. Developing immunotherapies is particularly important given the rise in the incidence of T1DM over the past 30 years, which is greatest in those presenting with the disease before they are 5 years old. 1 Whereas clini cal trials of immunotherapy have so far tar geted the adaptive immune system, Moran and colleagues 2 report two separate studies of thera pies directed against the innate immune system. They focused on antago nizing IL1β to reduce inflammation and protect the pancreas from further loss of βcell function within the first 3-4 months follow ing a diagnosis. 2 Two forms of anti IL1 treatment were used in randomized placebo controlled trials in patients with some residual insulin (>0.2 nmol/l Cpeptide after mixed meal tolerance stimu lation). An antiIL1 monoclonal antibody, canakinumab, or a recombi nant form of the naturally occurring IL1 receptor antagonist (IL1Ra), anakinra, were used to antagonize IL1. The only notable adverse events in the treatment groups compared with the placebo group were injectionsite re actions, which mainly occurred in patients receiv ing anakinra. Of importance, patients in the canakinumab and placebo groups both experienced neutro paenia, but further doses were not associated with sub sequent n eutropaenia in patients treated with canakinumab.
The multifactorial nature of T1DM pre sents several potential targets and pathways for immunotherapy. T cells, together with an inflammatory environment in the pancreatic islets, are generally accepted to have a key role in the death of insulinproducing β cells in patients with T1DM. Nevertheless, the development of T1DM has a strong environ mental component, which suggests that the innate immune system might also play an important part in the development of T1DM, especially in the early phases of the disease. The protracted development of the islet autoimmune response with loss of insulin productionthis process can span several yearspotentially provides many opportunities for intervention. However, we would need to predict who will progress to clinical T1DM and safely target the path ogenic components. The islet autoimmune response, with both effector and memory T cells targeting multiple autoantigens, is highly developed once clinical T1DM mani fests, which makes tackling single compo nents of the disease process at this time point much more difficult than early in the disease course.
Why focus on IL1? IL1 is a widely pro duced cytokine that has a major contri bution to the inflammation that occurs in response to tissue stress ( Figure 1 ). IL1 is produced by many types of cells, includ ing macrophages. In addition, islet β cells produce IL1 in vitro in response to hyper glycaemia. 3 Pancreatic islet β cells express IL1 receptors, and signalling occurs through the IL1 receptor 1 (Figure 1 ). Together with interferon γ and tumour necrosis factor, IL1 not only inhibits insulin secretion but also induces apoptosis. 4 IL1 also interfaces with the adaptive immune system, providing a signal for amplification of the responses of CD4 + T helper cells, and for differentiation of T cells that produce IL17. 5 Furthermore, the inflammatory microenvironment in the pancreatic islets, fuelled by the immune effectors and high levels of glucose, contri butes to damage the β cells, which are highly sensitive to such insults. 6 Thus, both theo retical and experimental evidence for a role of IL1 in inflammation of islet β cells pro vided a strong scientific ration ale 7 for the studies reported by Moran and colleagues. 
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as rare autoinflammatory syndromes such as familial Mediterranean fever. 8 This success, together with a preclinical rationale, 7 might have given hope that this treatment would be an alternative route to halting what has been an inevitable decline in βcell func tion in patients with T1DM. Unfortunately, this therapeutic option was not to be. T1DM is a very different organspecific autoimmune disorder to the systemic auto immune conditions, with a strong contribu tion from T cells. IL1, which is produced by macrophages and possibly islet β cells themselves, is probably only one of several pathogenic components.
Immunotherapy has generally been tested, of necessity, at the time of onset of T1DM. Did the late stage of disease at which Moran and colleagues tested the treatments contribute to the lack of efficacy? Two pos sible reasons exist for why this situation might have occurred. Firstly, the timing of the therapy for single interventions is prob ably very important. Any new therapy that is used at the time of presentation of T1DM must take into account the late stage of disease, at which point fully activated effec tor T cells infiltrating the islets are present, along with B cells and innate immune cells such as macrophages. An inflammatory islet milieu probably exists where β cells, which are highly sensitive to the presence of cytokines and oxidative stress, have either been destroyed or have reduced insulin secretion. Although IL1 probably has an important role in pathogenesis, the critical effect might be at an earlier stage in disease development; one could argue that this therapy might therefore be more effec tive before clinical manifestation of T1DM than at the stage tested by Moran and co workers. Secondly, given the multifaceted, fully activated immune response and the stressed target β cells, optimal therapy should address both these factors; a treat ment directed at a single component might not be sufficient.
Although limitations exist for the use of T1DM animal models, such as the non obese diabetic (NOD) mouse, genetically inactivating IL1 in mice as a single targeted mutation did not signifi cantly reduce the incidence of T1DM. 9 However, a pre clinical study in NOD mice has indicated that anak inra might be useful in combination with antiCD3 in NOD mice. 10 Of note, in this study of combined therapy, 10 mg anakinra per mouse per day were used, equating to about 400 mg/kg (for a mouse weighing ~25 g) over a short period of time, whereas in humans, the approved dose is 100 mg-250 times less than in mice (1.6 mg/kg for a bodyweight of ~60 kg) over a much longer time course. How these mouse model find ings translate to treatment of humans would need to be carefully considered.
For the present, as with other unsuccess ful treatments used as single agents in clinical trials of T1DM therapy to date, antiIL1 therapy should not be ruled out. We need to consider whether these treatments could be used safely in combination with other agents targeting different aspects of the disease process, and whether treatment can be implemented at an earlier stage in disease development than has been tested. The overall aim would be to reduce Tcell effector and memory responses, increase regulation in the immune system, redu ce inflammation, restore responses of remain ing β cells and regeneration or replace ment of β cells that will not be subject to further attack. Although these combina tion therapies will present safety challenges and obtaining approval by drug regulatory authorities will be difficult, tackling these issues will be vitally important. Figure 1 | IL-1 secretion and action on islet β cells. IL-1β is secreted after the IL-1β precursor is cleaved by caspase 1, produced from the NLRP3 inflammasome complex of proteins after activation by tissue stress. IL-1β binds to IL-1R1 and IL-1RAcP, inducing wide-ranging inflammatory effects. IL-1Ra is produced and secreted from cells expressing IL-1, with a circulating concentration of 100-300 ng/ml. IL-1Ra binds to IL-1 receptor, but does not induce signalling and antagonizes the effect of IL-1 by competition for binding to the receptor. In islets, IL-1β signals via a number of pathways, ultimately leading to apoptosis. Abbreviations: ASC, apoptosis-associated speck-like protein containing a CARD; ERK, extracellular signal regulated kinase; IL-1R1, IL-1 receptor 1; IL-1Ra, naturally occurring IL-1 receptor antagonist; IL-1RAcP, IL-1 receptor accessory protein; iNOS, inducible NO synthase; JNK, c-Jun N-terminal kinase; MyD88, Myeloid differentiation primary response gene (88); NF-κB, nuclear factor κB; NLRP3, NACHT, LRR and PYD domains-containing protein 3. 
